Kevin Becker, MD
Medical Oncology · Charleston, SCNPI 1023275633
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,028 of the $8,945 with a category attached, or 67.4%. 33 manufacturers reported payments, led by Eisai Inc. at 29.2% of the total. Reporting peaked in 2022 at $3,717 and has fallen 61.4% since, to $1,435 in 2025.
Across 139 payments — averaging $64.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$3K
- Foundation Medicine, Inc.$2K
- Johnson & Johnson$1K
- Novocure Inc.$685
- Novartis$618
- E.r. Squibb & Sons, L.L.C.$336
- plus $2K from 27 others
Across 51 payments — averaging $6983.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$150K
- Eli Lilly$122K
- Astrazeneca UK Limited$37K
- Beigene, Ltd.$23K
- E.r. Squibb & Sons, L.L.C.$12K
- AbbVie$5K
- plus $7K from 2 others
What the payments were for
- Consulting fees$6,02867%
- Food & beverage$2,79831%
- Education$1201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 2 | $2,608 |
| Foundation Medicine, Inc. | 1 | $1,500 |
| Johnson & Johnson | 9 | $1,491 |
| Novocure Inc. | 1 | $685 |
| Novartis | 43 | $618 |
| E.r. Squibb & Sons, L.L.C. | 19 | $336 |
| Merck | 10 | $220 |
| Pfizer | 8 | $155 |
| Stryker | 1 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $130 |
| Bayer | 2 | $105 |
| AstraZeneca | 5 | $105 |
| Astellas Pharma US Inc | 1 | $99 |
| Sanofi | 3 | $87 |
| Daiichi Sankyo Inc. | 3 | $73 |
| Lilly USA, LLC | 3 | $60 |
| Exelixis Inc. | 3 | $58 |
| Bristol Myers Squibb | 2 | $53 |
| Gilead | 3 | $50 |
| ADC Therapeutics America, Inc. | 2 | $48 |
| EMD Serono, Inc. | 1 | $42 |
| CMS Imaging, Inc. | 1 | $40 |
| Genmab U.S., Inc. | 1 | $32 |
| Karyopharm Therapeutics Inc. | 1 | $30 |
| Seagen Inc. | 1 | $25 |
| Puma Biotechnology, Inc. | 1 | $24 |
| Myovant Sciences Inc. | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Array Biopharma Inc | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $19 |
| Incyte Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$2,580
- FOUNDATIONONE CDX$1,500
- Erleada$1,263
- MAKO$132
How this compares
$8,945 in reported general payments places this provider in the 75th percentile of 29 medical oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 148 | $1,873,370 |
| LenvimaLenvatinib Mesylate | 21 | $475,737 |
| Abiraterone Acetate | 108 | $355,934 |
| TagrissoOsimertinib Mesylate | 18 | $299,736 |
| WeliregBelzutifan | 11 | $230,691 |
| OrgovyxRelugolix | 21 | $57,688 |
| Prednisone | 131 | $346 |
| Prochlorperazine Maleate | 20 | $197 |
| Potassium Chloride | 30 | $135 |
| Gabapentin | 11 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $99 | $1,873,370148 claims |
| Eisai Inc.Lenvima | $2,608 | $475,73721 claims |
| AstraZenecaTagrisso | $105 | $299,73618 claims |
| MerckWelireg | $220 | $230,69111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 29 medical oncology providers in South Carolina.
Other medical oncology in Charleston
- Albert LockhartCharleston$54K
- Gene SaylorsCharleston$26K
- Mariam AlexanderCharleston$23K
- Theodore GourdinCharleston$21K
- John KaczmarCharleston$20K
- Scott LindhorstCharleston$7K
- Carolyn BrittenCharleston$2K
- Rodney WilliamsCharleston$1K
- Oleksandra LupakCharleston$313
- Michael LillyCharleston$249
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.